A pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF)
1
Treatments such as TNF inhibitors might have a beneficial effect on cardiovascular risk.
2
TNF inhibitors are most cost-effective when used as last active therapy.
3
The ICERs for sequential use are of the same order as using the TNF inhibitor alone.
4
TNF inhibitors are most cost-effective when used last.
5
The next most cost-effective use of TNF inhibitors is third line, as recommended in the 2002 NICE guidance.
1
Conclusions: Ustekinumab has a significantly longer drug survival than the anti-TNF-a agents.
2
Recently chimeric anti-TNF-alpha has been introduced as a therapy for rheumatoid arthritis.
3
Treatment with anti-TNF also produced a nonsignificant trend for reduction in weight gain.
4
Administration of anti-TNF antiserum exacerbated the Ang II-mediated increase in mean arterial pressure.
5
The anti-TNF-a agent was discontinued at the time of diagnosis in two cases.
6
Randomization will be stratified according to the anti-TNF agent received before study inclusion.
7
The frequency of immunomodulator and anti-TNF use over time was assessed.
8
Only patients with anti-TNF administered for the first time were analysed.
9
A varIL26 genotype is associated with decreased levels of anti-TNF-a in CD patients.
10
Anti-TNF drugs are one of the most successful groups of all biologic medicines.
11
Intracerebroventricular infusion of an anti-TNF antibody blocked depression-like behavior and reduced persistent pain.
12
Cox regression analysis showed no beneficial correlations between anti-TNF timing and IBD-related complications.
13
All were long-lasting chronic-relapsing uveitis with prior failure to other anti-TNF-a.
14
Anti-TNF drugs are also used for other autoimmune disorders including Crohn's disease and psoriasis.
15
Its suppressive effect was partially reversed by anti-TNF-alpha neutralizing antibodies, thus proving its specificity.
16
The pneumococcal vaccination strategy should be optimized for patients with CD on anti-TNF therapy.
